FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively. FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:7.5 mg/ml (12.41 mM)

HCV: 200 nM, Rift Valley virus: 800 nM, HIV-1:150 nM, Ebola virus:（EC50）100 nM, Dengue Fever virus: 400-900 nM

In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM.

FGI-106??treatment decreases mortality from Zaire EBOV in a dose-dependent manner.